Optimization of targeted therapies to inhibit smooth muscle cell invasion in vitro

Author

Kennedy, C.E. ; Massia, S.P.

Author_Institution

Harrington Dept. of Bioeng., Arizona State Univ., Tempe, AZ, USA

Volume

2

fYear

2003

fDate

17-21 Sept. 2003

Firstpage

1215

Abstract

Vascular smooth muscle cell (VSMC) proliferation and migration has been correlated with intimal hyperplasia (IH) after vascular interventions such as angioplasty, stenting, and vascular graft surgery. Therefore, therapies targeting inhibition of VSMC migration may lead to higher patency rates in vascular grafts and reduced IH in other vascular interventions. This study tested three targeted therapies and their combinations: hyperfunctional α_vβ₃integrin expression, cyclic-RGD release and tissue inhibitor of metalloprotease (TIMP)-1 release. It was found that a combination of 1.0 mM cyclic-RGD and 10 ng/mL TIMP-1 maximally inhibited smooth muscle cell invasion over individual or other combinations of treatments over 72 hours.

Keywords

biological tissues; biomedical engineering; cardiovascular system; cell motility; diseases; muscle; proteins; surgery; 72 hours; angioplasty stenting; cell migration; cyclic-RGD release; hyperfunctional α_vβ₃integrin expression; intimal hyperplasia; optimization; targeted therapy; tissue inhibitor of metalloprotease (TIMP)-1 release; vascular graft surgery; vascular interventions; vascular smooth muscle cell proliferation; Angioplasty; Arteries; Biomembranes; Fluorescence; In vitro; Medical treatment; Muscles; Protocols; Sliding mode control; Surgery;

fLanguage

English

Publisher

ieee

Conference_Titel

Engineering in Medicine and Biology Society, 2003. Proceedings of the 25th Annual International Conference of the IEEE

ISSN

1094-687X

Print_ISBN

0-7803-7789-3

Type

conf

DOI

10.1109/IEMBS.2003.1279470

Filename

1279470